Department of Pharmacology, Graduate School of Medical and Dental Sciences, University of Kagoshima, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan.
FEBS Lett. 2012 Jun 12;586(12):1731-5. doi: 10.1016/j.febslet.2012.05.009. Epub 2012 May 15.
In addition to VPAC1 and VPAC2, PAC1 is involved in the pleiotropic action of pituitary adenylate cyclase activating polypeptide (PACAP) in the CNS. A luciferase reporter assay for the human PAC1 gene (-2160/+268) revealed that NGF treatment significantly augments the promoter activity of the PAC1 gene. Moreover, the Sp1 site at -282/-273 was shown to be essential for the NGF-augmented promoter activity of the PAC1 gene. Treatment with U0126, an MEK inhibitor, or Mithramycin A, an Sp1 inhibitor, significantly attenuated promoter activity. These results indicate that activation of Sp1 by the Ras/MAPK pathway might participate in neuron specific expression of the PAC1 gene.
除了 VPAC1 和 VPAC2,PAC1 还参与了垂体腺苷酸环化酶激活肽(PACAP)在中枢神经系统中的多效作用。人 PAC1 基因(-2160/+268)的荧光素酶报告基因检测显示,NGF 处理显著增强了 PAC1 基因的启动子活性。此外,-282/-273 处的 Sp1 位点对于 NGF 增强的 PAC1 基因启动子活性是必需的。用 MEK 抑制剂 U0126 或 Sp1 抑制剂米托蒽醌 A 处理,可显著减弱启动子活性。这些结果表明,Ras/MAPK 通路对 Sp1 的激活可能参与了 PAC1 基因在神经元中的特异性表达。